May 16, 2025
T cell engagers (TCEs) are bispecific antibodies designed to redirect cytotoxic T cells to pathogenic cells by simultaneously binding CD3 on T cells and disease-associated antigens on target cells.
Key limitations of T cell engager therapies include an incomplete understanding of primary resistance to treatment, which is influenced by the baseline composition of the T cell compartment and acquired resistance that is driven by T cell exhaustion.
In addition to supporting the assessment of safety and efficacy, CellCarta can also help you unravel the mechanisms at play behind primary and acquired resistance to TCE therapies.
